Business
Eli Lilly’s obesity pill remains a viable rival to Novo’s oral Wegovy despite data that underwhelmed investors
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024.
Scott Olson | Getty Images
Eli Lilly‘s stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that underwhelmed Wall Street.
In a key late-stage trial, Eli Lilly’s pill, orforglipron, caused less weight loss and had higher side effects than what analysts were expecting. The pill’s efficacy also appeared to come in slightly below that of Novo Nordisk‘s oral semaglutide for obesity, which showed strong data in a separate study.
Shares of Eli Lilly fell about 13% on the day the trial results were released, although they’re up about 12% since then.
But some analysts say Eli Lilly’s daily pill, if approved, could still be a viable competitor in the weight loss drug space — even if it will likely be second to enter the market. It’s a highly lucrative area that is eager for more convenient options that could ease the supply shortfalls and access hurdles created by the pricey weekly injections currently dominating it.
Analysts note that Eli Lilly’s pill could have a few advantages over the daily oral version of Novo Nordisk’s weight loss drug semaglutide, which is on track to become the first needle-free alternative for obesity to win approval in the U.S. later this year. Eli Lilly hopes to launch its pill globally “this time next year,” CEO David Ricks told CNBC in early August.
Both drugs work by mimicking a gut hormone called GLP-1 to suppress appetite and regulate blood sugar. But while Novo Nordisk’s pill is a peptide medication, orforglipron is a small-molecule drug.
That means Eli Lilly’s pill is absorbed more easily in the body and doesn’t require dietary restrictions like Novo Nordisk’s does. Orforglipron will also be easier to manufacture at scale, which is crucial as demand for obesity and diabetes injections outpaces supply.
Neither company has released prices for its respective pill, but some analysts said Eli Lilly’s drug could potentially have a lower price than Novo Nordisk’s pill. That would be a notable edge, as many health plans in the U.S. still don’t cover obesity treatments.
“It’s a little bit of an apples and oranges comparison because Novo Nordisk could have difficulty manufacturing enough of the product, given the high cost and requirements to manufacture oral semaglutide,” Leerink Partners analyst David Risinger said in an interview.
“Whereas Lilly plans to blanket the world with orforglipron, and very quickly it will generate dramatically more sales,” he continued. “It can launch globally in an extraordinary manner with lower prices and with no food intake consideration.”
Goldman Sachs analysts seem to agree, based on a note in August. They forecast daily oral pills will capture 24% share — or around $22 billion — of the 2030 global weight loss drug market, which they expect to be worth $95 billion.
The Goldman analysts said they expect Eli Lilly’s pill to have a 60% share — or roughly $13.6 billion — of the daily oral segment of the market in 2030. They expect Novo Nordisk’s oral semaglutide to have a 21% share — or around $4 billion — of that segment. The remaining 19% slice will go to other emerging pills, the analysts said.
The race to develop a more convenient obesity pill has been fraught, as companies such as Pfizer have had to scrap previous contenders and bring forward new ones. Novo Nordisk and Eli Lilly are also exploring other experimental oral drugs, along with a slate of other companies such as Viking Therapeutics, Structure Therapeutics, AstraZeneca and Roche.
In a statement, Novo Nordisk CEO Mike Doustar said “we strongly believe in the efficacy” of the oral drug. The Danish company added it will be “laser-focused on getting this product to patients without supply constraints” in the U.S.
Dr. Mihail “Misha” Zilbermint, director of endocrine hospitalists at Johns Hopkins Community Physicians, said it’s hard to crown a winner between Eli Lilly and Novo Nordisk without knowing how their respective pills will be priced and whether insurance will cover them.
“I think both of the drugs are going to be gamechangers,” he said. “When it comes to which company is going to win the game — cost is the biggest issue.”
Weight loss, side effect comparisons
It’s difficult to directly compare the results of separate clinical trials, especially as investors wait for Eli Lilly and Novo Nordisk to release the full data from their phase three studies.
Eli Lilly’s ATTAIN-1 trial also followed 3,000 patients, while Novo Nordisk’s OASIS 4 study evaluated a much smaller group of roughly 300. There are currently no studies directly comparing the two drugs, a Novo Nordisk spokesperson said.
But Novo Nordisk’s oral semaglutide appears to cause a greater level of weight loss than Eli Lilly’s pill based on the available data, said BMO Capital Markets analyst Evan Seigerman.
In the trial, the highest dose of Eli Lilly’s pill helped patients lose 12.4% of their body weight on average at 72 weeks. The pill’s weight loss was 11.2% when analyzing all patients regardless of discontinuations.
Wall Street had hoped Eli Lilly’s pill would generate weight loss of around 15%, the same level as Novo Nordisk’s blockbuster weight loss injection Wegovy. Semaglutide is the active ingredient in Wegovy and its diabetes counterpart Ozempic.
Novo Nordisk flags flutter outside its office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, on July 14, 2025.
Tom Little | Reuters
Meanwhile, the 25-milligram dose of Novo Nordisk’s oral semaglutide helped patients lose up to 16.6% of their weight on average at 64 weeks, according to results from the trial presented at a medical conference in 2024. That weight loss was 13.6% when the company analyzed all patients regardless of whether they stopped the drug.
A Novo Nordisk spokesperson added that 20% of weight loss was observed in nearly one-third of patients in the trial.
Still, the slightly lower efficacy of Eli Lilly’s pill may not be significant enough to deter patients from taking it.
“For many patients, 12% is a really great number,” said Seigerman. “There’s definitely a market there” for orforglipron.
In a note earlier this month, Bank of America analysts shared a similar sentiment.
“Yes, weight loss fell a bit short, but ask 100 prescribers whether this new data will really make a difference in who they’d put on orforglipron, and our belief is the vast majority would say, ‘not really,'” they wrote, referring to Eli Lilly’s trial data.
Some investors raised concerns about the side effects and discontinuation rates in the trial of Eli Lilly’s pill. But Seigerman said the drug’s tolerability data — how well patients tolerate it — appears to be relatively in line with that of Novo Nordisk’s oral semaglutide.
About 10.3% of patients who took the highest dose of Eli Lilly’s pill — 36 milligrams — discontinued treatment due to side effects, compared with around 2.6% of those who took a placebo.
Those side effects were mainly gastrointestinal, such as nausea and vomiting, and mild to moderate in severity. An estimated 24% of those who took the highest dose of Eli Lilly’s pill reported vomiting, while 33.7% had nausea.
Leerink’s Risinger said he is watching to see how persistent those gastrointestinal issues are once Eli Lilly presents the full data.
The side effects in the trial on Novo Nordisk’s pill were mostly gastrointestinal-related: 30.9% of those who took oral semaglutide reported vomiting and 46.6% reported nausea, according to the trial results.
Johns Hopkins’ Zilbermint said it’s difficult for him to decide which one has a better safety and tolerability profile based on the available data.
Meanwhile, Seigerman pointed to a different factor “that will also matter a lot”: dietary requirements.
Food requirements, manufacturing, price
Unlike Eli Lilly’s pill, patients need to take Novo Nordisk’s oral semaglutide in the morning on an empty stomach with no more than four ounces of plain water. They’re instructed to wait 30 minutes before eating, drinking or taking other oral medicines.
Seigerman said that could be a hurdle for some patients.
For example, “if you’re a parent with kids and you have to take this drug and wait half an hour before you can drink your coffee, you’re going to drive yourself crazy, especially if you have to take this every day,” he said. “I try to think about the real-world use of these drugs in a market like this. It’s going to matter.”
Leerink’s Risinger said oral semaglutide will also be “extremely expensive to manufacture” since it is a peptide medication, and “is likely going to have to be priced higher than orforlipgron.”
A Novo Nordisk spokesperson said the pill will be made mostly in the U.S., and the company is excited about the potential the pill “provides millions of Americans living with obesity.”
“Currently, all typical launch readiness activities [for the pill] are fully underway and building momentum,” the spokesperson said. They added that over the past decade, the company has invested $24 billion in the U.S. to expand manufacturing capacity and fuel research and development. That includes investments aimed at increasing manufacturing of active pharmaceutical ingredients and capacity for the final stages of production for both current and future injectable and oral products.
Small molecules are chemically simpler and easier to produce at scale, making them generally cheaper for companies to formulate. But it is still unclear how Eli Lilly will price orforglipron.
During an earnings call in August, Eli Lilly’s Ricks said the pricing will be based on the value orforglipron brings, considering health-care savings and the comorbidities it can address.
In the note earlier this month, Goldman Sachs analysts said they expect the pill to be “priced at parity” to Eli Lilly’s tirzepatide, the active ingredient in the company’s obesity injection Zepbound and diabetes counterpart Mounjaro, which list for just over $1,000 for a month’s supply.
“They should be cheaper than injections because they are easier to produce. But it does not mean they will be cheaper,” Johns Hopkins’ Zilbermint said. “We just don’t know — for example, we don’t know how much went into research and development.”
Seigerman said commercialization strategies will also be key when the pills compete on the market.
He questioned whether Novo Nordisk will lean into the deal it recently struck with CVS‘s pharmacy benefit manager, Caremark. Under the deal, Caremark started to prioritize Novo Nordisk’s Wegovy on its standard formularies on July 1, making that weekly injection the preferred GLP-1 drug for obesity over Zepbound.
But it is unclear whether oral semaglutide could receive a similar preferential status.
Seigerman also questioned whether Eli Lilly will offer orforglipron through its direct-to-consumer pharmacy, LillyDirect. That offering bypasses insurers and pharmacy benefit managers, allowing patients to directly purchase Zepbound and some of Eli Lilly’s other drugs from the company.
Seigerman said he expects “a lot of nuances in the go-to-market campaign for these drugs,” adding “that’s going to matter.”
Other competitors trail behind
Other obesity pills are in earlier stages of development, making it difficult to directly compare them to the drugs from Eli Lilly and Novo Nordisk without longer and larger trials.
But so far, some experts think they pale in comparison.
For example, Viking Therapeutics on Tuesday released mid-stage trial data that disappointed investors, sending its stock down as much as 40%.
Jared Holz, Mizuho health care equity strategist, said in an email Tuesday that the results on Viking’s drug “look inferior” to those of Eli Lilly’s pill “on almost all metrics.”
Viking’s once-daily pill helped patients lose up to 12.2% of their weight at around three months, with no plateau, which means patients could lose even more in a longer-term study.
Holz pointed to the high rate of patients who discontinued Viking’s drug for any reason over 13 weeks, which was around 28%. Meanwhile, around a quarter of people discontinued Eli Lilly’s pill, orforglipron, for any reason over 72 weeks.
That’s “a much longer trial and therefore [Lilly] looks far better head-to-head,” Holz said.
Business
Fundamental shift from savers to investors: What Indian households are doing with their money? – The Times of India
For years, Indian families have saved in gold, stored cash, and put money in tangible assets to safeguard their future. But now, there’s a noticeable shift is visible as more Indian households are moving away from old saving ways and putting their money to work through investments.India’s total household wealth, by the end of FY25, stood at Rs 1,300-1,400 lakh crore. Of this, investable financial assets stand at almost 35% of the total, growing at nearly 17% over the past five years, according to a recent Bain–Groww report, titled How India Invests.

Household wealth has gone through a shift since the Covid era. Indians have moved from traditional fixed deposits toward market-linked instruments like mutual funds, pension funds and listed equities, which are growing at a fast rate, far outpacing deposits growth.Over the last five years, individual investor base in the country has expanded sharply, going from around 3 crore investors in 2019 to over 12 crore by 2025, according to the Market Pulse December 2025 report by the National Stock Exchange of India (NSE), India. In 2025 alone, households invested a whopping Rs 4.5 lakh crore into equity markets, both directly and indirectly through mutual funds. This, pushed the overall household investment in equities since 2020 to around Rs 17 lakh crore. In FY25, mutual fund assets under management (AUM) held by individuals reached Rs 41 lakh crore, driven by double participation by households, going from 5–6% to 10–11%, and increasing popularity of systematic investment plans (SIPs).According to RBI data, equity formed 1.3% of household savings in FY2021, but its share increased to 2.1% by FY2025. Similarly, mutual funds recorded a significant jump over the same period, with their share rising sharply from 2.1% to 13.1%. Contributions to provident and pension funds also grew, increasing from 16.6% in FY2021 to 22.2% in FY2025.In contrast, traditional savings instruments saw a decline. Small savings, excluding PPF, fell from 7.9% to 6.5%, while the share of currency in household savings dropped steeply from 12.6% to 5.9%. Life insurance also witnessed a reduction, with its share slipping from 18.7% in FY2021 to 15% in FY2025.Gradually, households reduced their dependence on bank deposits and insurance-based savings. Instead, investments in pension schemes and mutual funds have gathered pace, pointing to a broader shift towards market-linked financial products.

Mutual funds, stocks, SIPs: Who is choosing what?
Salaried households show a clear preference for mutual funds, particularly through SIPs, reflecting a tilt toward disciplined, professionally managed investing aligned with long-term financial goals, according to the Bain report. In contrast, business owners display a stronger inclination toward direct equity investments, marked by higher trading frequency and a greater appetite for risk. Within mutual funds, SIPs remain the dominant entry route, while lump-sum investments are steadily gaining traction as investors mature, build market confidence, and increase their risk tolerance.
Interest in investing spiked after Covid?
Covid didn’t just change daily life, it changed how Indians invest. Retail participation in the stock market rose sharply after the pandemic, driven by a mix of high liquidity, lower household spending during lockdowns and the flexibility of work-from-home, Rohit Shah, Certified Financial Planner and founder of Getting You Rich told TOI. Shweta Rajani, head of mutual funds at Anand Rathi Wealth Limited, pointed out that mutual funds made up only 4–5% of household financial assets between FY15 and FY20, but this share nearly doubled from around 5% in FY20 to close to 10% by FY25. At the same time, direct equity investments also grew sharply, rising from about 4% of household assets in FY20 to around 9% by FY25. “Together, these shifts indicate a clear move away from traditional savings instruments towards market-linked investments, indicating investors are comfortable with equity as an asset,” the expert added.Meanwhile, Nirav Karkera, head of research at Fisdom believes that Covid acted more as an accelerator than a starting point as the shift had already begun after demonetisation. The switch made Indians comfortable with digital payments and later with digital investing. By the time the pandemic arrived, systems such as Aadhaar-based KYC, easy online transactions and awareness campaigns like Mutual Fund Sahi Hai had removed most barriers. “When the pandemic hit, investors suddenly had the time and urgency to reflect on their personal finances. More importantly, the infrastructure to execute decisions with almost zero friction already existed. Willingness, ability and accessibility came together and translated into action. The sharp and mostly linear market recovery that followed further strengthened confidence, pulled in fence-sitters and accelerated the broader financialisation of household assets that was underway,” Nirav added.
Change in India’s risk appetite
India’s shift from saving to investing is being driven less by thrill-seeking and more by necessity, experts said. Traditional savings instruments are increasingly failing to protect wealth, as post-tax returns often fall below inflation, steadily eroding purchasing power. “What looks like rising risk appetite is partly a change in the understanding of risk itself,” said Karkera, adding that investors now see the risk of staying idle and falling behind as greater than the risk of market volatility. This shift has been reinforced by deeper financial awareness, easier access to investing through fintech platforms, and stronger regulation, said Rajani. The expert further noted that SIPs, simplified KYC and digital onboarding have lowered entry barriers, while a generational change is reshaping attitudes, older investors prioritised capital preservation, but younger earners, facing higher inflation and lower real interest rates, are more focused on long-term wealth creation using growth assets. However Shah cautioned that rising participation does not always mean better risk management. “Four structural factors drive this shift: financial literacy campaigns, fintech accessibility reducing entry barriers, higher equity allocations in mutual fund inflows, and rising per capita incomes. Yet risk appetite may be overstated. Data on retail trading patterns shows concentration in speculative segments, suggesting investors confuse market participation with risk management. Many haven’t weathered a bear market, leading to underestimation of downside volatility,” Shah told TOI.
Here’s what is driving the investors:
A combination of demographic change, regulatory support, digital access and strong market returns has accelerated India’s move from traditional savings to investing.

Demographic changesYounger investors are driving India’s shift from traditional savings to investing, with NSE data showing that more than half newly registered investors are below 30. At the same time, women are steadily increasing their presence in financial markets. As of November 2025, women account for nearly a quarter of India’s investor base, with their share in the NSE’s individual investor pool remaining stable at almost 24%.Digital transformationDigital platforms have emerged as the main entry point for retail investors in the country, with almost 80% of direct equity investors and around 35% of mutual fund investors investing through digital channels. According to the Bain report, driven by app-based onboarding, paperless KYC and fintech-led distribution, platforms such as Groww, Zerodha and Upstox have simplified investing, brought in millions of first-time investors, and together account for almost 80% of India’s retail equity investor base.Going beyond metro citiesInvestment activity is increasingly coming from smaller cities. Around 55–60% of new SIP registrations now originate from B30 cities, highlighting the growing role of Tier-2 and Tier-3 regions in driving mutual fund growth.Rising financial literacy and awarenessThe spread of regional and digital financial content across YouTube, Instagram and fintech platforms has made investing concepts more accessible. Regulatory awareness campaigns by AMFI — including “Mutual Funds Sahi Hai” and “Bharat Nivesh Yatra” — have further boosted investor education.Market performance reinforcing trustSustained returns have strengthened long-term investor confidence. The Nifty 50 and Sensex delivered 10–15% returns over the last decade, while equity-oriented mutual funds have significantly outperformed traditional fixed deposits over the past five years.
Women and GenZ hit investment markets
GenZYounger investors are emerging as key drivers of the shift from traditional savings to investment. Data from the NSE shows that more than half, almost 56%, of newly registered investors are below 30. Mutual fund trends also reflected this shift, with 55% of investors under 40 and the 20–30 age group emerging as the fastest-growing segment in the top 100 cities.Comparing the contribution of GenZ and millennials, Rohit Shah said that according to the data, both cohorts contribute meaningfully, but with distinct patterns.“GenZ dominates app-based trading volumes due to digital nativity and lower capital requirements. Millennials drive mutual fund and long-term investments through larger disposable incomes and established goals.” He further added, after the market expansion happening after the pandemic, benefited both simultaneously, “making it difficult to isolate one generation as the primary driver. The real story lies in democratization across age groups, not generational dominance.The equity shift is broad-based across age groups according to AMFI’s age-wise distribution of individual investor AUM. Gen Z investors (under 25 years) have allocated nearly 65% of their assets to equity, Rajani told TOI. Millennials (25–44 years), meanwhile, “show the highest equity allocation at approximately 75.5%, and importantly, even investors above 58 years of age maintain a meaningful equity allocation of around 54%”Nirav Karkera, head of research at Fisdom, highlighted a different approach, saying that while millennials currently lead the equity surge, the baton is likely to pass to Gen Z in the coming years. “Gen Z is still in the early stage of their earning life, where consumption tends to dominate. At the same time, they are arguably the most financially aware generation we have seen. They understand the language of money much earlier than millennials did at their age. Once their incomes rise and they have surplus capital, they are likely to play an even bigger role than millennials in shaping investment patterns. For now, millennials are doing the heavy lifting, but the baton looks set to pass smoothly to Gen Z.”WomenAs of November 2025, women account for nearly a quarter of India’s investor base, highlighting their growing presence in financial markets. Data from NSE shows that over the corresponding period, women’s share in the individual investor base has remained stable at 24.7% over the corresponding period. Among the top five states by registered investors, Maharashtra leads with women comprising 28.8% of its investor pool, up from 25.6% in FY23, followed closely by Gujarat at 28.1% (26.6% in FY23). In contrast, Uttar Pradesh, despite being the second-largest state by investor count, continues to lag, with women forming 18.9% of investors, though this marks an improvement from 16.9% in FY23.Encouragingly, nearly 53% of Indian states now report female investor participation above the national average, compared to 44% in FY23. Smaller regions are emerging as frontrunners in gender inclusion, with Goa (33.1%), Mizoram (32.4%), Chandigarh (32.2%), Sikkim (31.1%) and Delhi (30.9%) leading the way – reflecting rising financial awareness, greater workforce participation, and improved access to investment avenues among women. Mutual funds also saw rising participation from women, particularly in B30 cities, where the share of women investors climbed from 20% to 25% over the past five years. In the top 30 cities, women now make up nearly 35% of mutual fund investors as of FY25, accompanied by a sharper rise in average MF folio sizes between FY19 and FY24.
Short-term or long-term: Where are Indians putting their money?
Indian investors are participating across both short-term trading and long-term wealth building, but experts say the balance is slowly tilting toward the latter. In the immediate post-Covid phase, many first-time investors entered markets with speculative intent. However, that period helped break psychological barriers. “Once investors experienced volatility firsthand rather than hearing about it abstractly, they started building familiarity, confidence and a basic understanding of market behaviour,” said Karkera, adding that the early rush acted as a gateway to more mature participation.Rajani told TOI that the trend is driven by long term objectives rather than short term. The expert pointed to AMFI’s SIP holding-period analysis, which shows that the share of SIP assets held for over five years has jumped from 11% to 29% in the past five years, while investments held for less than a year have fallen sharply from 41% to 23%.Meanwhile Shah said that even though “retail trading volumes have grown exponentially—NSE data shows consistent month-on-month increases in F&O participation. Simultaneously, mutual fund SIP adoption remains strong, but it’s overshadowed by trading activity. With fixed deposit yields compressed by falling interest rates, investors are chasing equity returns without corresponding time horizons. The evidence suggests a bifurcation: disciplined SIP investors versus growing trading populations driven by short-term performance metrics.”
Are there any risks for the investment express?
Shah warned that many new investors entered the market during a long bull run, and historically, market corrections of 30–50% happen every 7–10 years. Therefore, a prolonged downturn could lead to panic selling, especially among first-time investors with little experience of market volatility. Meanwhile, in the short term, market ups and downs may push some investors to move money into safer options like debt funds. Investors also tend to chase assets that have done well recently, such as gold and silver. However, Rajani pointed out that these shifts are temporary and not a fundamental change. “Over the long term, the broader trend toward equity investing is expected to continue as investors looking for inflation-beating returns to meet long-term financial goals.”Karkera also highlighted that even though risks remain, they are manageable. He noted that lower equity returns or bouts of market volatility could cause short-term, speculative investors to step back, and better performance in fixed-income or real assets may temporarily pull some money away from equities. However, the larger shift is firmly in place thanks to improved investor awareness, growing digital access. “Growth may pause or plateau intermittently, but the long-term trajectory of retail participation still feels upward.”
Still room to grow
Despite the rapid shift, India continues to lag developed markets. Mutual funds and equities account for just 15–20% of household investable assets, compared with 50–60% in countries like the US and Canada, highlighting significant headroom for future growth.As the Bain report notes: Over the next decade, mutual fund AUM is projected to cross Rs 300 lakh crore, while direct equity holdings could approach Rs 250 lakh crore, supported by deeper penetration in tier-2 and tier-3 cities, regulatory reforms and investor education initiatives.
Business
Green energy exports: $10-bn green ammonia project positions India as global clean-fuel supplier; Kakinada plant nears key milestone – The Times of India
A $10-billion green hydrogen and green ammonia project at Kakinada in Andhra Pradesh is set to cross a major construction milestone, reinforcing India’s ambition to emerge as a global supplier of clean energy to markets such as Germany, Japan and Singapore.The first major equipment erection ceremony of AM Green’s Green Hydrogen and Green Ammonia Complex will be held on January 17 and will be attended by Chief Minister N Chandrababu Naidu and Deputy Chief Minister Konidala Pawan Kalyan, state government officials said, PTI reported.Billed as one of the largest clean-energy investments in India to date, the project involves a total outlay of $10 billion and is expected to generate up to 8,000 jobs during the construction phase, besides substantial high-skill employment during operations and across allied sectors including renewable energy, logistics, storage and port services.AM Green is developing India’s first and the world’s largest green ammonia complex at Kakinada, with a planned capacity of 1.5 million tonnes per annum, through the brownfield conversion of an existing ammonia-urea facility. The project will be commissioned in phases, beginning with 0.5 million tonnes per annum by 2027, scaling up to 1 million tonnes by 2028 and reaching full capacity by 2030.Once operational, the facility will enable India’s first exports of green ammonia, which is increasingly being adopted globally as a clean shipping fuel, for power generation and as a carrier for green hydrogen.The integrated project spans 7.5 gigawatts of solar and wind capacity, 1,950 megawatts of electrolyser capacity and 2 gigawatts of round-the-clock renewable power, supported by pumped hydro storage, including India’s first such facility at Pinnapuram in Andhra Pradesh.AM Green has already signed long-term supply agreements with Germany-based utility Uniper and is in advanced discussions with potential buyers in Japan and Singapore, establishing India’s first green-energy export linkages with Europe and advanced Asian economies.The project is aligned with Andhra Pradesh’s Integrated Clean Energy Policy, 2024, which seeks to position the state as India’s primary hub for green hydrogen and green ammonia. Once fully commissioned, the facility is expected to mark a structural shift from energy import dependence towards clean-energy exports, placing Andhra Pradesh at the centre of the global green-energy value chain.AM Green, backed by the founders of the Greenko Group, is developing the project through AM Green Ammonia, a partnership involving Malaysia-based Gentari, Singapore’s sovereign wealth fund GIC and the Abu Dhabi Investment Authority. Construction at the Kakinada site is already under way, placing it among a limited set of large-scale green ammonia facilities globally that meet Renewable Fuels of Non-Biological Origin (RFNBO) standards.Beyond production, the project showcases an end-to-end clean-energy ecosystem within a single state, encompassing large-scale renewable generation, round-the-clock green power backed by storage, hydrogen and ammonia production, and port-based export infrastructure.AM Green has also moved to strengthen global linkages. In May last year, it announced a partnership with the Port of Rotterdam Authority to create a dedicated green-fuel corridor linking India with north-western Europe, aimed at enabling annual trade of up to 1 million tonnes of green fuels valued at nearly $1 billion. Earlier, it tied up with global logistics firm DP World to develop green fuel storage and export facilities in India and overseas.“This is not merely an industrial project, but a strategic step in positioning Andhra Pradesh and India as leaders in clean-energy exports and climate action,” the state government said.
Business
Budget 2026 Should Support MSMEs, Critical Minerals For Boosting Trade Resilience: Deloitte
Last Updated:
Deloitte India urges FY27 Budget to boost MSME support and critical mineral security, job protection and advancing India’s global manufacturing and clean energy goals.
Budget 2026 Expectations.
Budget 2026: Deloitte India has pitched a sharper focus on MSME support and critical mineral security in the FY27 Union Budget, arguing that these measures are essential to strengthen India’s trade resilience and reduce external vulnerabilities amid rising global uncertainty.
In its Budget expectations note, Deloitte India said micro, small and medium enterprises play a pivotal role in the economy, accounting for nearly 46% of India’s exports and emerging as the second-largest employer after agriculture. According to the firm, easing financial and compliance-related pressures on MSMEs would help them cope with global volatility, sustain production and remain competitive in overseas markets.
The Union Budget 2026-27 will be tabled on Sunday, February 1.
“Strengthening MSMEs will safeguard jobs and drive inclusive economic growth, boost rural incomes and support India’s ambition to become a global manufacturing hub,” Deloitte said.
The firm recommended measures such as enhanced export credit availability, concessional financing and simplified digital compliance systems to reduce the regulatory burden on small businesses. It also called for comprehensive training programmes to improve last-mile competitiveness of MSMEs, particularly those linked to global value chains.
Deloitte further suggested targeted export incentives or enhanced duty drawback support for tariff-sensitive sectors such as ready-made garments, gems and jewellery, and leather, which are more vulnerable to global trade disruptions.
Highlighting the risks from an increasingly protectionist global environment, Deloitte Economist Rumki Majumdar said rising uncertainty from tariff hikes, changes in rules of origin and non-tariff barriers could disproportionately affect Indian exporters. While the direct impact of global trade frictions on GDP growth may be limited to 40-80 basis points, the spillover effects on MSMEs and employment could be far more severe.
“MSMEs contribute 30.1 per cent to GDP, account for 45.79 per cent of India’s exports and employ nearly 290 million people; disruptions in export markets or tightening trade rules pose serious risks to jobs and income stability,” Majumdar said.
Beyond MSMEs, Deloitte emphasised the need for a strategic push on critical minerals to secure supply chains and support India’s clean energy transition. It proposed setting up a dedicated critical minerals fund to finance overseas acquisitions and technology partnerships, ensuring long-term access to essential resources.
The firm also recommended deeper global collaboration with regions such as Africa, Australia and Latin America to secure upstream access to minerals, alongside joint research and development in mineral processing and recycling. In addition, it called for incentives to promote investments in renewable energy, green hydrogen and grid-scale energy storage.
Deloitte said expanded funding for exploration, extraction and processing of key critical minerals, including lithium, cobalt and rare earth magnets, would be crucial to reduce import dependence and strengthen India’s strategic and economic security in the years ahead.
January 16, 2026, 15:02 IST
Read More
-
Politics1 week agoUK says provided assistance in US-led tanker seizure
-
Entertainment1 week agoDoes new US food pyramid put too much steak on your plate?
-
Entertainment1 week agoWhy did Nick Reiner’s lawyer Alan Jackson withdraw from case?
-
Sports5 days agoClock is ticking for Frank at Spurs, with dwindling evidence he deserves extra time
-
Business1 week agoTrump moves to ban home purchases by institutional investors
-
Sports1 week agoPGA of America CEO steps down after one year to take care of mother and mother-in-law
-
Tech4 days agoNew Proposed Legislation Would Let Self-Driving Cars Operate in New York State
-
Business1 week agoBulls dominate as KSE-100 breaks past 186,000 mark – SUCH TV
